Jazz Pharmaceuticals

What does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals makes prescription therapies in neuroscience and oncology. Key products include Xywav and Xyrem for sleep disorders, Epidiolex for epilepsy, Rylaze for leukemia, Zepzelca for lung cancer, and Defitelio for hepatic veno-occlusive disease.

Is Jazz Pharmaceuticals publicly traded?
Yes, Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker symbol JAZZ. The company is incorporated in Ireland and headquartered in Dublin.

Who founded Jazz Pharmaceuticals?
Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation. Cozadd continues to serve as Chairman and CEO.

Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland. The company maintains major operational hubs in Palo Alto, California and Philadelphia, Pennsylvania, with additional offices in Europe and Canada.

How many employees does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals employed approximately 2,890 people as of December 31, 2025. The company's workforce is distributed across research and development, manufacturing, and commercial operations.

Who owns Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker JAZZ. The company has a broad institutional shareholder base with no single controlling shareholder. Bruce Cozadd serves as Chairman and CEO.

Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation. The company went public on the Nasdaq in 2007.

Jazz's early growth was driven by Xyrem (sodium oxybate), a treatment for cataplexy and excessive daytime sleepiness in patients with narcolepsy. Xyrem became the company's primary revenue driver and at one point accounted for the majority of total revenue.

The company made several strategic acquisitions to diversify its portfolio. In 2014, Jazz acquired Gentium S.p.A. for approximately $1 billion, gaining Defitelio (defibrotide), a treatment for severe hepatic veno-occlusive disease. Later that year, Jazz acquired the Americas rights to defibrotide from Sigma-Tau Pharmaceuticals for $75 million upfront plus potential milestone payments.

In 2021, Jazz acquired GW Pharmaceuticals for approximately $7.2 billion, adding Epidiolex (cannabidiol), a treatment for seizures associated with epilepsy, to its neuroscience portfolio. This acquisition represented Jazz's largest deal and significantly expanded its neuroscience franchise.

For the year ended December 31, 2025, Jazz reported total revenue of approximately $4.27 billion, with product sales of approximately $4.02 billion. The company's largest product by revenue was Xywav with $1.66 billion in net sales, followed by Epidiolex with $1.06 billion.

Jazz has faced scrutiny regarding the pricing of Xyrem, which has been among the most expensive drugs in the United States. The company's patent strategies around Xyrem and Xywav have also drawn attention from regulators and generic manufacturers.

Jazz has also faced challenges related to the regulatory pathway for Defitelio, which initially received a Complete Response Letter from the FDA before ultimately gaining approval in 2016.